Cargando…
Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared?
At present, extracellular vesicles (EVs) are considered key candidates for cell-free therapies, including treatment of allergic and autoimmune diseases. However, their therapeutic effectiveness, dependent on proper targeting to the desired cells, is significantly limited due to the reduced bioavaila...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354279/ https://www.ncbi.nlm.nih.gov/pubmed/37476156 http://dx.doi.org/10.3389/fcell.2023.1211833 |
_version_ | 1785074894153711616 |
---|---|
author | Cieślik, Martyna Bryniarski, Krzysztof Nazimek, Katarzyna |
author_facet | Cieślik, Martyna Bryniarski, Krzysztof Nazimek, Katarzyna |
author_sort | Cieślik, Martyna |
collection | PubMed |
description | At present, extracellular vesicles (EVs) are considered key candidates for cell-free therapies, including treatment of allergic and autoimmune diseases. However, their therapeutic effectiveness, dependent on proper targeting to the desired cells, is significantly limited due to the reduced bioavailability resulting from their rapid clearance by the cells of the mononuclear phagocyte system (MPS). Thus, developing strategies to avoid EV elimination is essential when applying them in clinical practice. On the other hand, malfunctioning MPS contributes to various immune-related pathologies. Therapeutic reversal of these effects with EVs would be beneficial and could be achieved, for example, by modulating the macrophage phenotype or regulating antigen presentation by dendritic cells. Additionally, intended targeting of EVs to MPS macrophages for replication and repackaging of their molecules into new vesicle subtype can allow for their specific targeting to appropriate populations of acceptor cells. Herein, we briefly discuss the under-explored aspects of the MPS-EV interactions that undoubtedly require further research in order to accelerate the therapeutic use of EVs. |
format | Online Article Text |
id | pubmed-10354279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103542792023-07-20 Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? Cieślik, Martyna Bryniarski, Krzysztof Nazimek, Katarzyna Front Cell Dev Biol Cell and Developmental Biology At present, extracellular vesicles (EVs) are considered key candidates for cell-free therapies, including treatment of allergic and autoimmune diseases. However, their therapeutic effectiveness, dependent on proper targeting to the desired cells, is significantly limited due to the reduced bioavailability resulting from their rapid clearance by the cells of the mononuclear phagocyte system (MPS). Thus, developing strategies to avoid EV elimination is essential when applying them in clinical practice. On the other hand, malfunctioning MPS contributes to various immune-related pathologies. Therapeutic reversal of these effects with EVs would be beneficial and could be achieved, for example, by modulating the macrophage phenotype or regulating antigen presentation by dendritic cells. Additionally, intended targeting of EVs to MPS macrophages for replication and repackaging of their molecules into new vesicle subtype can allow for their specific targeting to appropriate populations of acceptor cells. Herein, we briefly discuss the under-explored aspects of the MPS-EV interactions that undoubtedly require further research in order to accelerate the therapeutic use of EVs. Frontiers Media S.A. 2023-07-05 /pmc/articles/PMC10354279/ /pubmed/37476156 http://dx.doi.org/10.3389/fcell.2023.1211833 Text en Copyright © 2023 Cieślik, Bryniarski and Nazimek. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Cieślik, Martyna Bryniarski, Krzysztof Nazimek, Katarzyna Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? |
title | Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? |
title_full | Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? |
title_fullStr | Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? |
title_full_unstemmed | Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? |
title_short | Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? |
title_sort | biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared? |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354279/ https://www.ncbi.nlm.nih.gov/pubmed/37476156 http://dx.doi.org/10.3389/fcell.2023.1211833 |
work_keys_str_mv | AT cieslikmartyna biodeliveryoftherapeuticextracellularvesiclesshouldmononuclearphagocytesalwaysbefeared AT bryniarskikrzysztof biodeliveryoftherapeuticextracellularvesiclesshouldmononuclearphagocytesalwaysbefeared AT nazimekkatarzyna biodeliveryoftherapeuticextracellularvesiclesshouldmononuclearphagocytesalwaysbefeared |